Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 398,237 | 361,426 | 327,026 | 352,299 | 453,500 |
| Receivables | 279,011 | 304,433 | 267,837 | 206,442 | 169,258 |
| Inventories | 121,058 | 152,772 | 161,283 | 146,362 | 98,545 |
| Other current assets | 11,782 | 12,372 | 12,119 | 22,408 | 30,847 |
| TOTAL | $833,897 | $859,974 | $811,428 | $766,331 | $796,767 |
| Non-Current Assets | |||||
| PPE Net | 3,379 | 3,836 | 4,195 | 4,345 | 4,790 |
| Other Non-Current Assets | 64,590 | 40,672 | 16,307 | 18,054 | 16,659 |
| TOTAL | $67,969 | $44,508 | $20,502 | $22,399 | $21,449 |
| Total Assets | $901,866 | $904,482 | $831,930 | $788,730 | $818,216 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 42,730 | 38,270 | 26,788 | 37,516 | 18,192 |
| Accrued Expenses | 139,835 | 122,781 | 101,399 | 127,806 | 117,089 |
| Other current liabilities | N/A | N/A | 77,287 | 75,830 | 44,610 |
| TOTAL | $191,260 | $169,168 | $215,291 | $247,593 | $185,630 |
| Non-Current Liabilities | |||||
| Long Term Debt | 358,982 | 364,025 | N/A | N/A | N/A |
| Deferred Revenues | 1,903 | 1,903 | 3,560 | N/A | N/A |
| Other Non-Current Liabilities | 114,503 | 106,962 | 349,963 | 346,616 | 400,315 |
| TOTAL | $473,485 | $470,987 | $349,963 | $346,616 | $400,315 |
| Total Liabilities | $664,745 | $640,155 | $565,254 | $594,209 | $585,945 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 124,393 | 121,766 | 121,366 | 120,582 | 118,500 |
| Common Shares | 12 | 12 | 12 | 12 | 12 |
| Retained earnings | -2,999,013 | -2,941,568 | -2,903,911 | -2,837,488 | -2,748,912 |
| Other shareholders' equity | -3,140 | -3,362 | -3,525 | -3,542 | -1,065 |
| TOTAL | $237,121 | $264,327 | $266,676 | $194,521 | $232,271 |
| Total Liabilities And Equity | $901,866 | $904,482 | $831,930 | $788,730 | $818,216 |